Daiichi Sankyo sees ENHERTU sales reaching ¥539.9B in FY2024 amid oncology momentum
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 31 2025
0mins
Source: SeekingAlpha
Financial Performance: Daiichi Sankyo reported a 16.6% year-on-year revenue increase to ¥1,367.6 billion for Q3 FY2024, primarily driven by strong sales of ENHERTU, which rose by ¥128.4 billion to ¥404.4 billion, and an upward revision of its global product sales forecast for ENHERTU to ¥539.9 billion for FY2024.
Outlook and Challenges: Despite delays in Datroway's approvals affecting future projections, management remains optimistic about sustaining growth through ENHERTU and has set a R&D spending target of ¥530 billion for FY2025, while addressing concerns over profitability pressures from vaccine sales uncertainties and high costs.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
